Ankasa Regenerative Therapeutics
Pre-clinicalStem cell renewal, maintenance and tissue regeneration are critical for normal health and well-being. Wnt pathway interactions are crucial to maintenance of these processes. Ankasa is the first to produce human Wnt proteins in a manufacturing setting suitable for use in humans.
Founded
2015
Focus
Cell & Gene Therapy
About
Stem cell renewal, maintenance and tissue regeneration are critical for normal health and well-being. Wnt pathway interactions are crucial to maintenance of these processes. Ankasa is the first to produce human Wnt proteins in a manufacturing setting suitable for use in humans.
Funding History
1Total raised: $10M
Seed$10MUndisclosedJun 15, 2021
Company Info
TypePrivate
Founded2015
LocationSan Diego, United States
StagePre-clinical
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile